ENGN

enGene Therapeutics Inc.

NASDAQ· Healthcare· Biotechnology

$1.83-4.45%

Key metrics

Market cap: $122.26M
P/E: —
Forward P/E: —
P/B: 0.5x
Dividend yield: —
EPS: -$2.18
ROE: -52.59%
Profit margin: 0.00%
Revenue growth: —
Beta: -0.28
52-week high: $12.25
52-week low: $1.40

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Employees: 81
Headquarters: Montreal, Canada
Website: engene.com

Company description provided by Yahoo Finance.